93O - First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)
|Date||27 March 2014|
|Session||Proffered Papers 1 - Advanced disease with tageted agents|
|Topics|| Drug Development
Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
H. Wakelee1, J. Soria2, R. Camidge3, S. Gadgeel4, J. Goldman5, A. Varga2, B. Solomon6, V. Papadimitrakopoulou7, P. Kaur8, L.V. Sequist9
Efficacy of existing EGFR tyrosine kinase inhibitors (TKIs) in NSCLC is limited by emergence of the T790M mutation in approximately 60% of patients, and significant skin rash and diarrhea, caused by wild-type (WT)-EGFR inhibition. CO-1686 is an oral, covalent TKI that targets common activating EGFR mutations and T790M, while sparing WT-EGFR.